



DATTA SINGLA & CO.
Chartered Accountants

SCO 2935-36, Level 1, Sector 22-C,
Chandigarh - 160 022 (INDIA)
Tele : +91-172-2707065, 5086551 / 52
Fax : +91-172-5019550

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter ended **June 30, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Datta Singla & Company
Chartered Accountants
Firm Regn. No. 006185N



Place: Chandigarh
Date: 14.08.2015

NECTAR LIFESCIENCES LIMITED



Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab), Corporate Identification Number: L24232PB1995PLC016664
Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: sunderlal@neclife.com, Website : www.neclife.com

Part I - Statement of Unaudited Financial Results for the Quarter ended 30.06.2015 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30-06-15	Quarter ended 31-03-15	Quarter ended 30-06-14	Year ended 31-03-15
		Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations				
	(a) Gross Sales	43152.19	45164.55	40213.54	174638.61
	Less : Excise Duty	2383.51	2818.70	2055.75	10349.72
	Net Sales	40768.68	42345.85	38157.79	164288.89
	(b) Other Operating Income	1.52	13.82	14.05	75.30
	Total Income from Operations (net)	40770.20	42359.67	38171.84	164364.19
2.	Expenses				
	(a) Cost of Materials consumed	25469.33	33097.02	25316.14	112990.38
	(b) Purchase of Stock in Trade	854.58	282.3	1424.17	3960.61
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	290.36	(3898.49)	(141.56)	(2817.56)
	(d) Employee benefits expense	1686.87	1918.47	1387.14	6270.67
	(e) Depreciation and amortisation expense	2178.71	1938.14	1923.26	7656.43
	(f) Other expenses	4413.68	5372.40	3612.30	17269.38
	Total Expenses	35893.53	38709.84	33521.45	145329.91
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	4876.67	3649.83	4650.39	19034.28
4.	Other Income	126.71	1281.62	230.23	1999.88
5.	Profit before finance costs and exceptional items (3+4)	5003.38	4931.45	4880.62	21034.16
6.	Finance costs	2733.24	2687.66	2840.11	12558.79
7.	Profit after finance costs but before exceptional items (5-6)	2270.14	2243.79	2040.51	8475.37
8.	Exceptional items	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2270.14	2243.79	2040.51	8475.37
10.	Tax Expense	528.80	572.76	415.47	1848.98
11.	Net Profit from ordinary activities after tax (9-10)	1741.34	1671.03	1625.04	6626.39
12.	Extraordinary item (net of tax expense)	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1741.34	1671.03	1625.04	6626.39
14.	Paid up Equity Share Capital (Face Value per share : Re 1/-)	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	93552.29
16.i	Earnings per Share (EPS) (before extraordinary items)				
	a) Basic	0.78	0.75	0.72	2.95
	b) Diluted	0.78	0.75	0.72	2.95
16.ii	Earnings per Share (EPS) (after extraordinary items)				
	a) Basic	0.78	0.75	0.72	2.95
	b) Diluted	0.78	0.75	0.72	2.95

Part II Select Information for the Quarter ended 30.06.2015

A Particulars of shareholding					
1.	Public Shareholding				
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	55,555,600	55,555,600	55,555,600	55,555,600
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.85	55.85	55.85	55.85
	- Percentage of Shares (as a % of the total share capital of the company)	24.77	24.77	24.77	24.77
	b) Non-encumbered				
	- Number of Shares	43,912,400	43,912,400	43,912,400	43,912,400
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.15	44.15	44.15	44.15
	- Percentage of Shares (as a % of the total share capital of the company)	19.58	19.58	19.58	19.58
B Investor Complaints		3 Months ended 30.06.2015			
	Pending at the beginning of Quarter	-			
	Received During the Quarter	3			
	Disposed Off During the Quarter	3			
	Pending at the end of Quarter	-			

Notes:

- The above financial results were reviewed by Audit Committee on 13.08.2015 and approved by the Board in its meeting held on 14.08.2015 and further limited reviewed by the Statutory Auditors of the Company.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- The above financial results are on stand alone basis.
- The company is exclusively in the pharmaceutical business segment.

By Order of the Board of Directors
of Nectar Lifesciences Limited

(Jhadesh Dua)

Chief Executive Officer & Director

Dated: 14.08.2015
Place: Chandigarh

